Rzerra (ofatumumab) - Recommendations To Screen, Monitor And To Manage Hepatitis B Virus Reactivation - For The Public

RZERRA Recall Summary RZERRA (ofatumumab) is a prescription medication that can cause hepatitis B virus to reactivate in people who carry the virus, potentially leading to serious liver disease. Health authorities are recommending that patients taking this drug be screened for hepatitis B, monitored during treatment, and managed appropriately if reactivation occurs. This alert applies to all RZERRA users across Canada.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2014-01-27

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/4c2200ae-249f-4e87-86c6-fc9c71bf5d0e